NCT02030574View on ClinicalTrials.gov

Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Invasive Bladder CancerBladder Cancer
Interventions
DRUG

Gemcitabine and fractionated cisplatin (combination treatment)

1 Cycle = 21 days. GC x 4 cycles ----\> cystectomy Gemcitabine: 1000mg/m2, days 1 and 8 Cisplatin: 35mg/m2, days 1 and 8

Trial Locations (2)

02903

Rhode Island Hospital (including Newport Hospital and East Greenwich), Providence

02906

The Miriam Hospital, Providence

Sponsors

Lead Sponsor

Brown University
All Listed Sponsors
collaborator

Lifespan

OTHER

lead

Brown University

OTHER

NCT02030574 - Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin | Biotech Hunter | Biotech Hunter